person · Reporting owner

Crane Rosemary A

Disclosed activity across 6 companies

Tapewire entity: 40718
SEC CIK: 0001443343

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Catalent, Inc.CTLT · Entity 16279	Director	October 27, 2023	October 31, 2023
TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063	Director	June 05, 2026	June 08, 2026
Tarsus Pharmaceuticals, Inc.TARS · Entity 1836	Director	June 24, 2024	June 25, 2024
Unilife CorpUNIS · Entity 12414	Director	October 28, 2016	November 07, 2016

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Catalent, Inc.

Report date October 27, 2023 · Filed October 31, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	23,873	Reported balance After 2023-10-27 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2023-10-27 · Grant · Acquired 6,993 · Balance 23,873 F1: The equity acquired by the reporting person is the annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-employee director compensation program. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award, subject to continued service. F2: Includes restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: The equity acquired by the reporting person is the annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-employee director compensation program. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award, subject to continued service.

F2: Includes restricted stock units.

TEVA PHARMACEUTICAL INDUSTRIES LTD

Report date June 05, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	127,739	Reported balance After 2026-06-05 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-05 · Exercise / conversion · Acquired 14,492 · Balance 127,739 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-05 · Exercise / conversion · Disposed 14,492 · Balance 0 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.

Tarsus Pharmaceuticals, Inc.

Report date June 24, 2024 · Filed June 25, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,350	Reported balance After 2024-06-24 transaction · row 1 1 source row Row 1 · 2024-06-24 · Exercise / conversion · Acquired 3,350 · Balance 5,350 F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-06-24 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-06-24 · Exercise / conversion · Disposed 3,350 · Balance 0 F2: Each RSU represents a contingent right to receive one share of the Company's common stock. F3: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

F2: Each RSU represents a contingent right to receive one share of the Company's common stock.

F3: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Unilife Corp

Report date October 28, 2016 · Filed November 07, 2016

This filing explicitly reported no securities owned.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Certara, Inc.

Report date May 14, 2026 · Filed May 15, 2026

Section 16 reporting ended · disclosed 2026-05-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	45,672	Reported balance After 2026-05-14 transaction · row 1 1 source row Row 1 · 2026-05-14 · Exercise / conversion · Acquired 15,757 · Balance 45,672 F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-14 · Exercise / conversion · Disposed 15,757 · Balance 0 F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.

PDS Biotechnology Corp

Report date March 15, 2019 · Filed March 18, 2019

Section 16 reporting ended · disclosed 2019-03-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,000	Reported balance After 2019-03-15 transaction · row 1 1 source row Row 1 · 2019-03-15 · Exercise / conversion · Acquired 10,000 · Balance 10,000 F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-03-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-03-15 · Exercise / conversion · Disposed 10,000 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018. F3: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F4: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.

Filing footnotes · ownership attribution and instrument terms

F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018.

F2: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit.

F3: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria.

F4: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 11, 2020 Filed Aug 13, 2020 20:07 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	7,956	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-046581 · doc4.xml · nonDerivative · entry 1 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
June 11, 2020 Filed Jun 15, 2020 11:31 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	17,621	$0.00	$0.00	Disclosure SEC source: 0001209191-20-036495 · doc4.xml · derivative · entry 2 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,621 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 11, 2019 and vested on June 11, 2020. F3 · derivative.expiration_date: Restricted share units were granted on June 11, 2019 and vested on June 11, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 11, 2020 Filed Jun 15, 2020 11:31 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	17,621	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-036495 · doc4.xml · nonDerivative · entry 1 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
June 09, 2020 Filed Jun 11, 2020 11:10 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	GrantRestricted Share Units · Derivative	12,668	$0.00	$0.00	Disclosure SEC source: 0001209191-20-035781 · doc4.xml · derivative · entry 1 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,668 Underlying: Ordinary Shares · 12,668 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 9, 2020 and vest on June 9, 2021. F2 · derivative.expiration_date: Restricted share units were granted on June 9, 2020 and vest on June 9, 2021. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
August 22, 2019 Filed Aug 26, 2019 19:46 UTC	Catalent, Inc. CTLT · Entity 16279	GrantCommon Stock	3,167	$0.00	$0.00	Disclosure SEC source: 0001596783-19-000154 · wf-form4_156684878535142.xml · nonDerivative · entry 1 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,543 F1 · kind: The equity acquired by the reporting person is the regular, annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-management director compensation package. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award. F2 · balance_after: Includes restricted stock units. Read SEC document
June 11, 2019 Filed Jun 13, 2019 10:18 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	GrantRestricted Share Units · Derivative	17,621	$0.00	$0.00	Disclosure SEC source: 0001209191-19-036588 · doc4.xml · derivative · entry 1 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,621 Underlying: Ordinary Shares · 17,621 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 11, 2019 and vest on June 11, 2020. F2 · derivative.expiration_date: Restricted share units were granted on June 11, 2019 and vest on June 11, 2020. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
May 16, 2019 Filed May 20, 2019 11:00 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	2,780	$0.00	$0.00	Disclosure SEC source: 0001209191-19-031205 · doc4.xml · derivative · entry 2 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,780 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on May 16, 2016 and vested on May 16, 2019. F3 · derivative.expiration_date: Restricted share units were granted on May 16, 2016 and vested on May 16, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
May 16, 2019 Filed May 20, 2019 11:00 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	2,780	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-031205 · doc4.xml · nonDerivative · entry 1 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
March 15, 2019 Filed Mar 18, 2019 21:36 UTC	PDS Biotechnology Corp EDGE · Entity 7939	Exercise / conversionRestricted Stock Units · Derivative	10,000	$0.00	$0.00	Disclosure SEC source: 0001127602-19-011907 · form4.xml · derivative · entry 2 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F1 · kind: Vesting of RSUs granted to the Reporting Person on August 14, 2018. F3 · derivative.exercise_date: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F4 · derivative.expiration_date: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest. Read SEC document
March 15, 2019 Filed Mar 18, 2019 21:36 UTC	PDS Biotechnology Corp EDGE · Entity 7939	Exercise / conversionCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001127602-19-011907 · form4.xml · nonDerivative · entry 1 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of RSUs granted to the Reporting Person on August 14, 2018. Read SEC document
September 03, 2018 Filed Sep 5, 2018 20:06 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	2,162	$0.00	$0.00	Disclosure SEC source: 0001209191-18-049512 · doc4.xml · derivative · entry 2 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,162 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on October 7, 2015 and vested on September 3, 2018. F3 · derivative.expiration_date: Restricted share units were granted on October 7, 2015 and vested on September 3, 2018. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
September 03, 2018 Filed Sep 5, 2018 20:06 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	2,162	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-049512 · doc4.xml · nonDerivative · entry 1 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
August 23, 2018 Filed Aug 24, 2018 18:48 UTC	Catalent, Inc. CTLT · Entity 16279	GrantCommon Stock	4,183	$0.00	$0.00	Disclosure SEC source: 0001596783-18-000067 · wf-form4_153513647797371.xml · nonDerivative · entry 1 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,376 F1 · kind: The equity acquired by the reporting person is the regular, annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-management director compensation program. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award. F2 · balance_after: Includes restricted stock units. Read SEC document
August 14, 2018 Filed Aug 15, 2018 12:07 UTC	PDS Biotechnology Corp EDGE · Entity 7939	GrantRestricted Stock Units · Derivative	10,000	$0.00	$0.00	Disclosure SEC source: 0001127602-18-025378 · form4.xml · derivative · entry 1 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F2 · derivative.exercise_date: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F3 · derivative.expiration_date: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest. Read SEC document
June 19, 2018 Filed Jun 20, 2018 20:30 UTC	PDS Biotechnology Corp EDGE · Entity 7939	GrantStock Option (Right To Purchase) · Derivative	20,000	$0.00 Strike: $1.10	$0.00	Disclosure SEC source: 0001127602-18-021584 · form4.xml · derivative · entry 1 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F2 · derivative.expiration_date: These options expire on the third anniversary of the vesting date. Read SEC document
June 05, 2018 Filed Jun 7, 2018 10:50 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	GrantRestricted Share Units · Derivative	6,041	$0.00	$0.00	Disclosure SEC source: 0001209191-18-036202 · doc4.xml · derivative · entry 1 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,041 Underlying: Ordinary Shares · 6,041 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 5, 2018 and vest on June 5, 2021. F2 · derivative.expiration_date: Restricted share units were granted on June 5, 2018 and vest on June 5, 2021. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
September 18, 2017 Filed Sep 20, 2017 13:08 UTC	PDS Biotechnology Corp EDGE · Entity 7939	GrantStock Option (Right To Purchase) · Derivative	30,000	$0.00 Strike: $9.43	$0.00	Disclosure SEC source: 0001127602-17-027793 · form4.xml · derivative · entry 1 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-09-18 F1 · derivative.exercise_date: One third of the option shares vest upon each of the first, second, and third anniversaries of the Transaction Date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.